Inventor · disambiguated record
Charles Michael Zacharchuk
Also filed as: ZACHARCHUK CHARLES · ZACHARCHUK CHARLES M · ZACHARCHUK CHARLES MICHAEL
6 granted patents·14 pending applications·28 citations·filing 2006–2022
79Inventor score
Top patents by PatentIndex Score
20 records- 0183US8669273B2Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabineZACHARCHUK CHARLES MICHAEL·Filed 2009·Granted Mar 11, 2014·13 cites·23 claims
- 0279US9511063B2Antineoplastic combinations containing HKI-272 and vinorelbineWYETH LLC·Filed 2013·Granted Dec 6, 2016·4 cites·46 claims
- 0374US8338456B2Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitorCOUGHLIN CHRISTINA MARIE·Filed 2011·Granted Dec 25, 2012·11 cites·20 claims
- 0474US2023201155A1Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272WYETH LLC·Filed 2022·Application pending·0 cites
- 0571US2022354820A1Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272WYETH LLC·Filed 2021·Application pending·0 cites
- 0669US2022170107A1Phosphatidylinositol-3-kinase pathway biomarkersWYETH LLC·Filed 2021·Application pending·0 cites
- 0763US2009312360A1Antineoplastic Combinations Containing HKI-272 and VinorelbineWYETH CORP·Filed 2009·Application pending·0 cites
- 0862US10729672B2Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272WYETH LLC·Filed 2013·Granted Aug 4, 2020·0 cites·14 claims
- 0962US9265784B2Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabineWYETH LLC·Filed 2014·Granted Feb 23, 2016·0 cites·23 claims
- 1062US2009297519A1ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272WYETH CORP·Filed 2009·Application pending·0 cites
- 1158US2010069340A1Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitorWYETH CORP·Filed 2009·Application pending·0 cites
- 1257US10111868B2Antineoplastic combinations containing HKI-272 and vinorelbineWYETH LLC·Filed 2016·Granted Oct 30, 2018·0 cites·17 claims
- 1355US2019271047A1Phosphatidylinositol-3-kinase pathway biomarkersWYETH LLC·Filed 2019·Application pending·0 cites
- 1454US2007104721A1Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272WYETH CORP·Filed 2006·Application pending·0 cites
- 1549US2012270896A1Antineoplastic Combinations Containing HKI-272 and VinorelbineZACHARCHUK CHARLES MICHAEL·Filed 2012·Application pending·0 cites
- 1649US2012308560A1Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272MOORE LAURENCE·Filed 2012·Application pending·0 cites
- 1746US2016222467A1Phosphatidylinositol-3-kinase pathway biomarkersWYETH LLC·Filed 2016·Application pending·0 cites
- 1846US2010081666A1Src activation for determining cancer prognosis and as a target for cancer therapyWYETH CORP·Filed 2009·Application pending·0 cites
- 1941US2013189274A1Phosphatidylinositol-3-kinase pathway biomarkersBERKENBLIT ANNA·Filed 2010·Application pending·0 cites
- 2040US2006235046A1Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patientsWYETH CORP·Filed 2006·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →